UnitedHealth Appoints Dr. Scott Gottlieb to Board of Directors

Overview of Appointment

UnitedHealth has announced the addition of Dr. Scott Gottlieb, the former commissioner of the Food and Drug Administration (FDA), to its board of directors. This move is part of the healthcare giant’s ongoing efforts to revamp its leadership and governance teams, effective immediately as of Tuesday.

Background on Dr. Gottlieb

Dr. Gottlieb served as the FDA commissioner from 2017 to 2019 during the initial Trump administration and was widely respected throughout his tenure. His involvement comes at a critical juncture for UnitedHealth as the company seeks to navigate various operational, regulatory, and public relations challenges.

Challenges Facing UnitedHealth

Recent Struggles

In recent years, UnitedHealth has faced escalating medical expenses, a significant cyberattack, and federal antitrust investigations. The situation intensified following the tragic death of the company’s top insurance executive late last year, leading to increased scrutiny and concerns among investors. Consequently, the company’s stock has declined by 39% year to date, despite implementing a turnaround strategy that has shown some signs of success.

Leadership Changes

Stephen Hemsley, the chairman of UnitedHealth’s board and newly appointed CEO following the unexpected departure of Andrew Witty, has prioritized improving the company’s relationship with regulators. Dr. Gottlieb’s extensive experience with regulatory agencies may provide valuable support in this endeavor.

Dr. Gottlieb’s Regulatory Experience

Career Highlights

Dr. Gottlieb has held various roles in both the public and private sectors. Before becoming FDA commissioner in May 2017, he worked for the FDA, the Centers for Medicare & Medicaid Services (CMS), and the Health and Human Services (HHS) advisory committee on health IT policy. His appointment to the FDA was generally well-received, particularly in contrast to some of the earlier, unconventional choices of the Trump administration.

Achievements at the FDA

During his time at the FDA, Dr. Gottlieb championed initiatives to accelerate the approval of generic drugs and boost the availability of biosimilar medications. He also addressed pressing issues like the opioid crisis and the regulation of e-cigarettes, which had previously received less attention. Despite facing concerns about anticompetitive practices during his tenure, he was regarded favorably for expediting the approval process for drugs and medical devices.

Post-FDA Career

After resigning from the FDA just before the COVID-19 pandemic, Dr. Gottlieb became a senior fellow at the American Enterprise Institute and joined the venture capital firm New Enterprise Associates. He has also taken positions on the boards of several health technology and biopharmaceutical companies. His rapid appointment to the board of Pfizer shortly after leaving the FDA raised discussions regarding potential conflicts of interest related to the “revolving door” phenomenon between regulatory agencies and the industries they oversee.

Statements from Leadership

UnitedHealth’s Perspective

UnitedHealth has not disclosed specific reasons for Dr. Gottlieb’s appointment. However, CEO Stephen Hemsley described him as an “innovator” advocating for a “more integrated healthcare approach” enhanced by advanced technology.

Dr. Gottlieb’s Vision

In his statement, Dr. Gottlieb expressed enthusiasm about collaborating with UnitedHealth to shape the development and accessibility of medical breakthroughs for patients who could benefit. He aims to utilize his experience to support healthcare providers in delivering care that is not only innovative but also more affordable, ultimately improving outcomes for patients and communities.

Future Directions for UnitedHealth

Changes in Leadership and Governance

Since assuming the role of CEO, Hemsley has initiated several leadership changes, including the appointment of a new CFO. In August, UnitedHealth announced the formation of a new “public responsibility” board committee aimed at enhancing corporate governance and monitoring regulatory risks. The company has not confirmed whether Dr. Gottlieb will participate in any specific committees.